Hypothalamic Corticotrophin Releasing Hormone and Norepinephrine Contribute to Sympathoexcitation in Heart Failure

Yu-Ming Kang,Xiao-Jing Yu,Yan-Lin Guo,Ning Yan,Jie Qi,Li-Min Yang,Da-Nian Qin,Carrie Elks,Joseph Francis
DOI: https://doi.org/10.1096/fasebj.24.1_supplement.1019.7
2010-01-01
Abstract:Systemic administration of tumour necrosis factor (TNF)‐α induces the release of norepinephrine (NE) in the paraventricular nucleus (PVN) of hypothalamus and an increase in expression of corticotrophin releasing hormone (CRH) and CRH type 1 receptors. NE converges in the PVN to influence its neuronal activity. We explored the hypothesis that CRH and norepinephrine in PVN mediate the sympathetic responses to HF. Sprague‐Dawley rats with HF or SHAM rats were treated for 4‐weeks with a continuous bilateral PVN infusion of the CRH antagonist α‐helical CRH (αh‐CRH) or the α1‐adrenergic antagonist prazosin, or artificial cerebrospinal fluid (aCSF). HF rats had higher levels of norepinephrine (NE) and tyrosine hydroxylase (TH) and lower level of nNOS in the PVN when compared to SHAM rats. Plasma levels of cytokines, NE, epinephrine and angiotensin II, were increased in HF rats; renal sympathetic nerve activity (RSNA) was also increased in these animals. Bilateral PVN infusions of the CRH antagonist αh‐CRH attenuated the increases in PVN NE and TH in HF rats. Bilateral PVN infusions of the CRH antagonist αh‐CRH or the α1‐adrenergic antagonist prazosin attenuated, the decrease in PVN nNOS, the increases in plasma levels of cytokines, NE and angiotensin II and in RSNA in HF rats. This study demonstrates that norepinephrine and CRH in the PVN contribute to sympathoexcitation in heart failure.
What problem does this paper attempt to address?